Biosyent Inc.(RX-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low13.850
Day High14.050
Open:13.850
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
BioSyent to Present at Planet MicroCap Las Vegas
GlobeNewswire
BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)
GlobeNewswire
BioSyent Declares Second Quarter 2026 Dividend
GlobeNewswire
BioSyent Releases Financial Results for First Quarter 2026
GlobeNewswire
BioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026
GlobeNewswire
BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
FeraMAX is Canada's Top-Ranked Iron Supplement for 11 Consecutive Years
GlobeNewswire
BioSyent Announces Grant of Restricted Share Units
GlobeNewswire
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
GlobeNewswire
BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026
GlobeNewswire
BioSyent Announces Closing of the Acquisition of Oral Science Inc.
Newsfile
Upcoming Meeting Dates - February 16, 2026
GlobeNewswire
BioSyent to Acquire Oral Science Inc.
GlobeNewswire
BioSyent Declares First Quarter 2026 Dividend
GlobeNewswire
BioSyent Announces Renewal of Normal Course Issuer Bid
GlobeNewswire
BioSyent Releases Financial Results for Q3 and YTD 2025
GlobeNewswire
BioSyent Declares Fourth Quarter 2025 Dividend
KeyStone Financial
Beyond the S&P 500: Finding Overlooked Opportunities in Small Caps
Road sign of New York Wall street corner Broad street by Mezzotint via Shutterstock
Motley Fool
3 AI Stocks Disrupting Trillion-Dollar Industries

Profile

Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It markets and delivers a diverse range of healthcare products, including over-the-counter, behind-the-counter, and prescription options. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX Pd, Inofolic, Gelclair, Cathejell, RepaGyn, Proktis-M, and Tibella. The company derives revenue from pharmaceutical and insecticide business. Geographically, it derives maximum revenue from Canada and also has its presence internationally.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.